• Profile
Close

Tocilizumab in patients hospitalized with Covid-19 pneumonia

New England Journal of Medicine Dec 23, 2020

Salama C, Han J, Yau L, et al. - Researchers sought to clarify the safety as well as the efficacy of tocilizumab (the anti–interleukin-6 receptor antibody) in patients from underserved and racial and ethnic minority populations who were hospitalized with coronavirus disease 2019 (Covid-19) pneumonia. Patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation were randomized (in a 2:1 ratio) to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. Mechanical ventilation or death by day 28 was the primary outcome. Findings revealed that a decrease in the probability of progression to the composite outcome of mechanical ventilation or death was conferred by treatment with tocilizumab in hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, however, tocilizumab failed to improve survival. In addition, there were no new safety signals.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay